Medtronic plc MDT commercially launched MiniMed 670G system, a Hybrid Closed Loop insulin delivery system for Type I diabetic patients. This happened following the U.S. FDA approval late last year.

Medtronic plc MDT announced that the FDA has approved a new arm indication for the Guardian Sensor 3 continuous glucose monitor (CGM) used with the MiniMed 670G insulin pump. Notably, the Guardian ...

When Medtronic won approval for the MiniMed 670G from the FDA in 2016, it was a big deal. Advertised as “The World’s First Hybrid Closed Loop System,” it is the first commercial product of its kind – ...

Medtronic touted new clinical data from its growing base of MiniMed 670G insulin-pump users, noting on Tuesday that people who used the pump's most advanced features kept their blood sugar levels ...

The company's announcement notably does not use the term "artificial pancreas," although the technology is a considerably more significant advance from the 530G threshold suspend device of 2013. When ...

Medtronic says real-world data show its MiniMed 670G glucose management system increased time in range for people with diabetes. Medtronic has announced clinical outcomes for the MiniMed 670G system, ...

Medtronic plc.'s MDT Diabetes Management segment is dominating the headlines of late. Following the company’s receipt of the CE Mark approval for its advanced continuous glucose monitoring (CGM) ...